Quarterly report pursuant to Section 13 or 15(d)

Investments - Narrative (Details)

v3.21.1
Investments - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]    
Total assets of equity method investees $ 2,519,575 $ 2,473,063
Total liabilities of equity method investees 823,061 801,512
Market value 7,600  
Equity Method Investment, Nonconsolidated Investee or Group of Investees    
Schedule of Equity Method Investments [Line Items]    
Total assets of equity method investees 109,500 90,900
Total liabilities of equity method investees 23,900 28,400
Net losses of equity method investees $ 10,100 $ 75,400
Pharmsynthez    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 9.00%  
Cocrystal    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 4.00%  
Number of shares into which warrants may be converted (in shares) 33,000  
Non-Invasive Monitoring Systems, Inc.    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 1.00%  
Neovasc    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 1.00%  
InCellDx, Inc    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 29.00%  
Number of shares into which warrants may be converted (in shares) 700,000  
BioCardia, Inc.    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 1.00%  
Ownership percentage 1.00%  
Number of shares into which warrants may be converted (in shares) 47,000  
Xenetic Biosciences, Inc.    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 2.00%  
Number of shares into which warrants may be converted (in shares) 40,000  
Phio Pharmaceuticals    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage 0.01%  
Number of shares into which warrants may be converted (in shares) 404  
VBI Vaccines Inc    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage 1.00%  
ChromaDex    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage 0.10%  
MabVax Therapeutics Holdings, Inc.    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage 1.00%  
Eloxx Pharmaceuticals    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage 3.00%  
Detect Genomix | Variable Interest Entity, Not Primary Beneficiary    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 49.00%  
Additional investment in equity method investment $ 245  
Zebra | Variable Interest Entity, Not Primary Beneficiary    
Schedule of Equity Method Investments [Line Items]    
Ownership percentage, equity method 29.00%  
Series A Preferred Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary    
Schedule of Equity Method Investments [Line Items]    
Investment owned (in shares) 1,260,000  
Restricted Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary    
Schedule of Equity Method Investments [Line Items]    
Shares received as a gift (in shares) 900,000